Trials / Conditions / Refractory T-Cell Lymphoma

Refractory T-Cell Lymphoma

6 registered clinical trials studyying Refractory T-Cell Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106	The First Affiliated Hospital of Xiamen University	Phase 2
Terminated	CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma NCT04217317	Wake Forest University Health Sciences	Phase 2
Terminated	Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH NCT04251065	Fondazione Italiana Linfomi - ETS	Phase 2
Unknown	Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Hae NCT04470947	Medical University of Vienna	—
Unknown	CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies NCT04162340	iCell Gene Therapeutics	Phase 1
Terminated	A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma NCT01878708	Dana-Farber Cancer Institute	EARLY_Phase 1